These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32213306)

  • 1. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.
    Daudén E; Carretero G; Rivera R; Ferrándiz C; Llamas-Velasco M; de la Cueva P; Belinchón I; Gómez-García FJ; Herrera-Acosta E; Ruiz-Genao DP; Ferrán-Farrés M; Alsina M; Baniandrés-Rodríguez O; Sánchez-Carazo JL; Sahuquillo-Torralba A; Fernández-Freire LR; Vilar-Alejo J; García-Donoso C; Carrascosa JM; Herrera-Ceballos E; López-Estebaranz JL; Botella-Estrada R; Segovia-Muñoz E; Descalzo MA; García-Doval I;
    J Am Acad Dermatol; 2020 Jul; 83(1):139-150. PubMed ID: 32213306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.
    Dávila-Seijo P; Dauden E; Descalzo MA; Carretero G; Carrascosa JM; Vanaclocha F; Gómez-García FJ; De la Cueva-Dobao P; Herrera-Ceballos E; Belinchón I; López-Estebaranz JL; Alsina M; Sánchez-Carazo JL; Ferrán M; Torrado R; Ferrandiz C; Rivera R; Llamas M; Jiménez-Puya R; García-Doval I;
    J Invest Dermatol; 2017 Feb; 137(2):313-321. PubMed ID: 27677836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
    Carretero G; Ferrandiz C; Dauden E; Vanaclocha Sebastián F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina-Gibert M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Carazo C; Rivera R; Jiménez-Puya R; García-Doval I;
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):156-63. PubMed ID: 24684267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
    Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
    Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis.
    Dávila-Seijo P; Dauden E; Carretero G; Ferrandiz C; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Llamas M; Rivera R; Jiménez-Puya R; García-Doval I;
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):1942-1950. PubMed ID: 27329511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
    Belinchón I; Ramos JM; Carretero G; Ferrándiz C; Rivera R; Daudén E; De la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Llamas-Velasco M; Ortiz PL; García-Doval I; Descalzo MA;
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1700-1708. PubMed ID: 28485816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
    JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
    Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
    J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry.
    Medina C; Carretero G; Ferrandiz C; Dauden E; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Carrascosa JM; Torrado R; Argila D; Rivera R; Jiménez-Puya R; García-Doval I;
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):858-64. PubMed ID: 25185962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis.
    Lunder T; Zorko MS; Kolar NK; Suhodolcan AB; Marovt M; Leskovec NK; Marko PB
    Int J Dermatol; 2019 Jun; 58(6):631-641. PubMed ID: 30973647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.
    Lluch-Galcerá JJ; Carrascosa JM; González-Quesada A; Rivera-Díaz R; Sahuquillo-Torralba A; Llamas-Velasco M; Gómez-García FJ; Herrera-Acosta E; de la Cueva P; Baniandrés-Rodríguez O; Lopez-Estebaranz JL; Belinchón I; Ferrán M; Mateu A; Rodríguez L; Riera-Monroig J; Abalde-Pintos MT; Carretero G; García-Donoso C; Pujol-Marco C; Del Alcázar E; Santamaría-Domínguez C; Suárez-Pérez JA; Nieto-Benito LM; Ruiz-Genao DP; Salgado-Boquete L; Descalzo MÁ; García-Doval I
    Br J Dermatol; 2024 Feb; 190(3):355-363. PubMed ID: 37846976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
    Hugh J; Van Voorhees AS; Nijhawan RI; Bagel J; Lebwohl M; Blauvelt A; Hsu S; Weinberg JM
    J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis.
    Dommasch ED; Kim SC; Lee MP; Gagne JJ
    JAMA Dermatol; 2019 Oct; 155(10):1142-1152. PubMed ID: 31075163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
    Egeberg A; Ottosen MB; Gniadecki R; Broesby-Olsen S; Dam TN; Bryld LE; Rasmussen MK; Skov L
    Br J Dermatol; 2018 Feb; 178(2):509-519. PubMed ID: 29094341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry.
    Bonomo L; Abittan BJ; Hashim PW; Karki C; Mason M; Lebwohl M
    J Drugs Dermatol; 2019 Aug; 18(8):731-740. PubMed ID: 31424705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
    Gottlieb AB; Kalb RE; Langley RG; Krueger GG; de Jong EM; Guenther L; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Menter A
    J Drugs Dermatol; 2014 Dec; 13(12):1441-8. PubMed ID: 25607786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report].
    Rivera R; García-Doval I; Carretero G; Daudén E; Sánchez-Carazo J; Ferrándiz C; Herrera E; Alsina M; Ferrán M; López-Estebaranz JL; Gómez F; Herranz JM; Carrascosa JM; Vanaclocha F;
    Actas Dermosifiliogr; 2011 Mar; 102(2):132-41. PubMed ID: 21377137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study.
    Iannone LF; Bennardo L; Palleria C; Roberti R; De Sarro C; Naturale MD; Dastoli S; Donato L; Manti A; Valenti G; D'Amico D; D'Attola S; De Francesco AE; Bosco V; Donato Di Paola E; Nisticò SP; Citraro R; Russo E; De Sarro G
    PLoS One; 2020; 15(11):e0241575. PubMed ID: 33141869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry.
    Munera-Campos M; Vilar-Alejo J; Rivera R; Carrascosa JM; Daudén E; Herrera-Acosta E; Sahuquillo-Torralba A; Gómez-García FJ; Baniandrés-Rodríguez O; de la Cueva P; López-Estebaranz JL; Belinchón I; Ferran M; Riera-Monroig J; Rodriguez L; Carretero G; García-Donoso C; Ballescá F; Llamas-Velasco M; Herrera-Ceballos E; Pujol-Marco C; Nieto-Benito LM; Ruiz-Genao DP; Alsina M; Descalzo MA; García-Doval I;
    J Dermatolog Treat; 2022 Jun; 33(4):2110-2117. PubMed ID: 33913796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.